The article presents the results of studying the impact of α-glucosidase inhibitors on body weight and main carbohydrate metabolism indicators. The authors note the positive effects of drugs from this group on all components of metabolic syndrome, safety for the body, absence of serious contraindications and low level of hypoglycemia. Voglibose as representative of α-glucosidase inhibitors can be effectively used in combination with metformin, as well as together with insulin therapy
The gradual decline in β-cell function is inevitable in type 2 diabetes mellitus and therefore, subs...
The article presents the results of using new antihyperglycemic drug — a selective inhibitor of the ...
Background. The early prescription of a combination of extended-release metformin with glimepiride i...
The aim of the study — clinical and metabolic rationale for the selection of the third hypoglycemic ...
New therapeutic options to control diabetes mellitus (DM) emerged with the discovery of alpha-glucos...
Objective of the study — an estimation of efficiency of application and tolerability of new alpha-gl...
The article explains the early use of a combination of glucose-lowering drugs that act on different ...
Type 2 diabetes mellitus is a major health problem associated with excess morbidity and mortality. A...
Floris Alexander van de LaarRadboud University Nijmegen Medical Centre, Department of General Practi...
Aim. Substantiation of necessity of pathogenetic approach to the choice of method for type 2 diabete...
Insulin is the mainstay of current treatment for patients with type 1 diabetes mellitus (T1DM). Due ...
More than 65 million Americans are currently obese. Type 2 diabetes mellitus, frequently seen in obe...
Background: Diabetes mellitus (DM) is a spectrum of metabolic disorders as a consequence of differen...
peer reviewedObesity is a well-known risk factor for non-insulin-dependent (or Type 2) diabetes mell...
In type 2 diabetes mellitus (T2DM), the development and progression of cardiovascular diseases occur...
The gradual decline in β-cell function is inevitable in type 2 diabetes mellitus and therefore, subs...
The article presents the results of using new antihyperglycemic drug — a selective inhibitor of the ...
Background. The early prescription of a combination of extended-release metformin with glimepiride i...
The aim of the study — clinical and metabolic rationale for the selection of the third hypoglycemic ...
New therapeutic options to control diabetes mellitus (DM) emerged with the discovery of alpha-glucos...
Objective of the study — an estimation of efficiency of application and tolerability of new alpha-gl...
The article explains the early use of a combination of glucose-lowering drugs that act on different ...
Type 2 diabetes mellitus is a major health problem associated with excess morbidity and mortality. A...
Floris Alexander van de LaarRadboud University Nijmegen Medical Centre, Department of General Practi...
Aim. Substantiation of necessity of pathogenetic approach to the choice of method for type 2 diabete...
Insulin is the mainstay of current treatment for patients with type 1 diabetes mellitus (T1DM). Due ...
More than 65 million Americans are currently obese. Type 2 diabetes mellitus, frequently seen in obe...
Background: Diabetes mellitus (DM) is a spectrum of metabolic disorders as a consequence of differen...
peer reviewedObesity is a well-known risk factor for non-insulin-dependent (or Type 2) diabetes mell...
In type 2 diabetes mellitus (T2DM), the development and progression of cardiovascular diseases occur...
The gradual decline in β-cell function is inevitable in type 2 diabetes mellitus and therefore, subs...
The article presents the results of using new antihyperglycemic drug — a selective inhibitor of the ...
Background. The early prescription of a combination of extended-release metformin with glimepiride i...